942 related articles for article (PubMed ID: 23048057)
1. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
[TBL] [Abstract][Full Text] [Related]
2. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
3. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
4. Scaffold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a 3-year serial optical coherence tomography study.
Zhang YJ; Iqbal J; Nakatani S; Bourantas CV; Campos CM; Ishibashi Y; Cho YK; Veldhof S; Wang J; Onuma Y; Garcia-Garcia HM; Dudek D; van Geuns RJ; Serruys PW;
JACC Cardiovasc Interv; 2014 Dec; 7(12):1361-9. PubMed ID: 25457053
[TBL] [Abstract][Full Text] [Related]
5. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.
Windecker S; Haude M; Neumann FJ; Stangl K; Witzenbichler B; Slagboom T; Sabaté M; Goicolea J; Barragan P; Cook S; Piot C; Richardt G; Merkely B; Schneider H; Bilger J; Erne P; Waksman R; Zaugg S; Jüni P; Lefèvre T
Circ Cardiovasc Interv; 2015 Feb; 8(2):e001441. PubMed ID: 25634905
[TBL] [Abstract][Full Text] [Related]
9. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
[TBL] [Abstract][Full Text] [Related]
10. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
Serruys PW; Onuma Y; Garcia-Garcia HM; Muramatsu T; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Ormiston JA
EuroIntervention; 2014 Mar; 9(11):1271-84. PubMed ID: 24291783
[TBL] [Abstract][Full Text] [Related]
12. Serial observation of drug-eluting absorbable metal scaffold: multi-imaging modality assessment.
Waksman R; Prati F; Bruining N; Haude M; Böse D; Kitabata H; Erne P; Verheye S; Degen H; Vermeersch P; Di Vito L; Koolen J; Erbel R
Circ Cardiovasc Interv; 2013 Dec; 6(6):644-53. PubMed ID: 24254708
[TBL] [Abstract][Full Text] [Related]
13. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
[TBL] [Abstract][Full Text] [Related]
14. A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.
Teeuwen K; Adriaenssens T; Van den Branden BJ; Henriques JP; Van der Schaaf RJ; Koolen JJ; Vermeersch PH; Bosschaert MA; Tijssen JG; Suttorp MJ
Trials; 2012 Dec; 13():240. PubMed ID: 23241457
[TBL] [Abstract][Full Text] [Related]
15. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities.
Simsek C; Karanasos A; Magro M; Garcia-Garcia HM; Onuma Y; Regar E; Boersma E; Serruys PW; van Geuns RJ
EuroIntervention; 2016 Jan; 11(9):996-1003. PubMed ID: 25349042
[TBL] [Abstract][Full Text] [Related]
16. Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.
Brugaletta S; Gomez-Lara J; Serruys PW; Farooq V; van Geuns RJ; Thuesen L; Dudek D; Koolen J; Chevalier B; McClean D; Windecker S; Smits PC; de Bruyne B; Whitbourn R; Meredith I; van Domburg RT; Sihan K; de Winter S; Veldhof S; Miquel-Hebert K; Rapoza R; Garcia-Garcia HM; Ormiston JA; Bruining N
JACC Cardiovasc Interv; 2011 Dec; 4(12):1281-9. PubMed ID: 22192369
[TBL] [Abstract][Full Text] [Related]
17. Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold: evidence in vivo about the abluminal healing process.
Gutiérrez-Chico JL; Gijsen F; Regar E; Wentzel J; de Bruyne B; Thuesen L; Ormiston J; McClean DR; Windecker S; Chevalier B; Dudek D; Whitbourn R; Brugaletta S; Onuma Y; Serruys PW
JACC Cardiovasc Interv; 2012 Apr; 5(4):428-35. PubMed ID: 22516401
[TBL] [Abstract][Full Text] [Related]
18. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S
JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155
[TBL] [Abstract][Full Text] [Related]
19. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
Serruys PW; Ormiston J; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Chevalier B; Smits P; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Wasungu L; Ediebah D; Veldhof S; Onuma Y
J Am Coll Cardiol; 2016 Feb; 67(7):766-76. PubMed ID: 26892411
[TBL] [Abstract][Full Text] [Related]
20. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
